Ögren S.O., Kehr J., Schött P.A. and Snitt K. Effects of the neuropeptide galanin on hippocampal acetylcholine and cognition: a novel approach for treatment of impaired cholinergic function. Pharmacology and Toxicology, 80 (Suppl. 1), 8 (1997). Trends in Neuroprotective Drugs: Design, Pharmacology and Clinics. International Conference. Riga, Latvia, May 29-June 1, 1997.
Ögren S.O., Kehr J., Schött P.A. and Snitt K. Galanin receptors and their functional characterization. European Neuropsychopharmacology, 7 (Suppl. 2), S104-S105 (1997). European College of Neuropsychopharmacology (ECNP).
Schött P.A., Bjelke B. and Ögren S.O. Time-dependent effects of intrahippocampal galanin on spatial learning. Relationship to distribution and kinetics (1998). Wenner- Gren foundation.
Åhlander M.U., Misane I., Schött P.A. and Ögren S.O. Behavioural analysis of the spatial learning deficit induced by Dizocilpine (MK-801). European Neuropsychopharmacology, 8 (Suppl. 2), S240 (1998). ECNP.
Hökfelt T., Xu Z.-Q., Sergeyev V., Diez M., Broberger C., Holmberg K., Ubink R., Schött P., Ögren S.O., Kahl U., Bartfai T., Lendahl U., Hurd Y., Petersson S., Lavebratt K., Johansen J., Schalling M., Koistinaho J., Kahn K., Games D., DeArmond S.J. and Prusiner S. The mode of action of neuropeptides and its relevance for brain diseases. European Neuropsychopharmacology, 10 (Suppl. 3), S121-S122 (2000). ECNP.
Hökfelt T., Xu Z.-Q.D., Holmberg K., Kehr J., Schött P., Ögren S.O., Wang F.-H., Yoshitaki T., Bartfai T., Lendahl U., Kokaia M., Nanobashvili A., Kokaia Z., Lindvall O., Kahl U. and Yamaguchi M. Monoamine-neuropeptide interactions. European Neuropsychopharmacology, 11 (Suppl. 3), S116-S117 (2001). ECNP.
Hökfelt T., Xu Z.-Q.D., Holmberg K., Kehr J., Schött P.A., Ögren S.O., Wang F.-H., Yoshitaki T., Bartfai T., Lendahl U., Kokaia M., Nanobashvili A., Kokaia Z., Lindvall O., Kahl U. and Yamaguchi M. Peptide receptors: Anything different from targeting amine systems? European Neuropsychopharmacology, 12 (Suppl. 3), S169-S170 (2002). ECNP.
Elvander E., Schött P.A., Kehr J., Mannström P., Bjelke B. and Ögren S.O.Medial septal galanin and spatial learning in the rat: Role of in vivo acetylcholine release in the hippocampus. European Neuropsychopharmacology, 12 (Suppl. 3), S374-S375 (2002). ECNP .
Schött P .A., Rask A., Nilsson Y ., Staflund A. And Bhat R.V . GSK3β over-expressing mice – a mouse model for Alzheimer’s disease? European Neuropsychopharmacology, 13 (Suppl. 4), S391-S392 (2003). ECNP.
Schött P., Gruber S., Georgievska B., Ahlgren C., The-Minh T., Groblewski T, and Nordström E. AZD5213, a novel selective H3 receptor antagonist. Effect on neurotransmitter release and cognitive performance in rodents. 12th International Stockholm / Springfield Alzheimer Symposium on Advances in Alzheimer Therapy, (2012).
Ahlgren C., Schött P., Juréus A., Jonström P., Takano A., Nyberg S., and Nordström E. AZD5213, a novel selective histamine H3 receptor antagonist: Receptor occupancy and imaging in rodents and primate brain. 12th International Stockholm / Springfield Alzheimer Symposium on Advances in Alzheimer Therapy, (2012).
Lundkvist J., Schött P., Klintenberg R., Gruber S., Appelkvist P., Strömberg K., Arvidsson P., Georgievska B., and Sandin J. γ-Secretase inhibitor treatment results in impaired behavior in the contextual fear conditioning test in the mouse. 12th International Stockholm / Springfield Alzheimer Symposium on Advances in Alzheimer Therapy, (2012).
